Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Edap Tms Q3 2026 Results: Net Loss of $4.46M, Loss Narrows

EDAP TMS reported total revenues of $34.6 million for the first nine months of 2026, a significant increase from $23.8 million in the prior year period. Despite higher gross profits, the company saw an expanded operating loss of $23.8 million due to increased selling, marketing, and administrative expenses, alongside a net loss of $28.0 million for the period.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue9.87.8
Gross profit5.13.6
Profit before tax-5.3-6.6
Net income-4.5-5.9
EPS (diluted, $ a share)$-0.10$-0.16

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+25.5%
Gross margin51.4%
Operating margin-79.1%
Source

10-Q filed with the SEC, NASDAQ: FOCL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Edap Tms SA: key numbers

Share price
$3.17Close, Nov 16
Market cap
$150M
Shares outstanding
47.22MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Electromedical & Electrotherapeutic ApparatusSIC 3845

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Edap Tms SA

All →
4:15 PM ET 8-K
Financial Results

Edap Tms Financial Results

EDAP TMS (FocalTherics) reported Q3 2026 revenue of $9.8 million, a 26% increase year-over-year, driven by a 32% increase in U.S. procedure volume and seven Focal One system sales. The company narrowed its full-year 2026 revenue guidance to $50.0-$52.0 million, representing 34% to 39% growth over 2025.

Term
Q3 2026

“We demonstrated steady commercial momentum in the third quarter, highlighted by expanding adoption across multiple new regions and additional system sales in the United States, Turkey, Mexico, and France. U.S. procedure volumes accelerated year-over-year to 32% for the third quarter of 2026, compared to 15% in 2025. Driven by our sustained commercial traction, accelerating technology adoption, and our focus on our HIFU opportunity, we remain highly confident in our growth strategy and on the opportunity ahead as we close out the year.”

Ryan Rhodes, CEO of FocalTherics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.